Read the case “Transferring Innovation Across National Boundaries,” Write a 5 page paper (1500 or more words) in APA format Read the case “Transferring Innovation Across National Boundaries,”
Read the case “Transferring Innovation Across National Boundaries,” Write a 5 page paper (1500 or more words) in APA format
Read the case “Transferring Innovation Across National Boundaries,”
Write a 5 page paper (1500 or more words) in APA format
Below is a recommended outline.
Cover Page
Introduction
A thesis statement
Purpose of paper
Overview of paper
Body
How could the three forms of data collection be used together in the opening stages of the change process at Minnesota Biolabs?
Define how the Informal Design Elements for Building High Commitment would apply to this case.
What predictions would you make for the success of getting the country general managers in Europe and Japan to adopt the new product?
Conclusion – Summary of main points
Lessons Learned and Recommendations
5. References – List the references you cited in the text of your paper according to APA format and REFERENCED DOCUMENT MUST BE MAXIMUM 5 YEARS.
CASE STUDY
TRANSFERRING INNOVATION ACROSS NATIONAL BOUNDARIES Imagine entering a hospital for treatment of a medical condition only to come down with a far more serious, perhaps even life-threatening disease caused by that very treatment. That, unfortunately, is an increasingly common experience in hospitals located in the United States and elsewhere. The culprit is often an infection transferred to the patient through a tainted “injectable”: that is, a needle, an IV drip, and so forth. This is known as a sepsis infection: an overwhelming infection of the blood stream resulting from toxin-producing bacteria (endotoxins). National health regulatory agencies seek to limit such negative outcomes by requiring that products intended for injection be tested.
Minnesota Biolabs Traditionally, tests for sepsis infection were performed on live animals—rabbits, for the most part—lead to the animal’s death. Minnesota Biolabs (MB) was one of the companies that supplied rabbits to the producers of injectable devices. Headquartered in suburban Minneapolis, MB served customers—mainly pharmaceuticals but also university and private laboratories—in over 20 countries. Europe was divided into three MB national units, MB-France, MB-Germany, and MB-United Kingdom. A fourth country unit, MB-Japan, served Asian markets. Each of those four units—France, Germany, the United Kingdom, and Japan—was managed by a country general manager. That general manager was typically left alone to operate his or her unit autonomously. Corporate headquarters set annual growth goals for the units and measured their profit and loss. As long as the units performed according to those goals, the managers were paid a bonus and mostly left alone. Strategies, product decisions, and acquisitions were determined by corporate executives in the States and communicated to these country managers. MB’s CEO frequently said that he liked this approach to management because it delineated clear lines of authority and responsibility. Country managers also preferred this autonomy. They were allowed, they believed, to decide on local strategies that best served their customers while maintaining good relation- ships with the national regulatory agencies to which they needed to respond. MB’s exceptional history of sustained, profitable growth reinforced the belief of managers that this was a well-designed organization.
. .
The post Read the case “Transferring Innovation Across National Boundaries,” Write a 5 page paper (1500 or more words) in APA format Read the case “Transferring Innovation Across National Boundaries,” appeared first on My Nursing Writer.
